<DOC>
	<DOCNO>NCT01122680</DOCNO>
	<brief_summary>The primary objective trial evaluate efficacy safety tiotropium 1.25 mcg ( 2 actuation 0.625 mcg ) , tiotropium 2.5 mcg ( 2 actuation 1.25 mcg ) tiotropium 5 mcg ( 2 actuation 2.5 mcg ) daily even deliver Respimat inhaler adolescent ( 12 17 yr ) moderate persistent asthma , compare placebo top maintenance therapy inhale corticosteroid controller medication . It randomise , double-blind , placebo-controlled Phase II trial incomplete cross-over design . Patients need still symptomatic , i. e. fully control maintenance treatment .</brief_summary>
	<brief_title>Efficacy Safety 3 Doses Tiotropium Compared Placebo Adolescents ( 12 17 Yrs ) With Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient legally accept caregiver ( ) must sign date Informed Consent form consistent Good Clinical Practice ( GCP ) guideline International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use ( ICH ) local legislation prior participation trial . 2 . Male female patient 12 17 year age . 3 . All patient must least 3 month history asthma fulfill diagnostic criterion moderate persistent asthma , accord current Global Initiative Asthma ( GINA ) guideline time enrolment trial . 4 . All patient must maintenance treatment inhaled corticosteroid stable medium dose least 4 week Visit 1 . 5 . All patient must symptomatic ( partly control ) Visit 1 ( screen ) prior randomisation Visit 2 define Asthma Control Questionnaire ( ACQ ) mean score equal 1.5 . 6 . All patient must prebronchodilator FEV1 60 % less equal 90 % predict normal Visit 1 . Variation absolute FEV1 value Visit 1 ( prebronchodilator ) compare Visit 2 ( predose ) must within ± 30 % . 7 . All patient must increase FEV1 equal 12 % 200 mL 15 min . 400 mcg salbutamol ( albuterol ) Visit 1 . If patient low age range ( e.g. , 12 14 year old ) exhibit small total lung volume , positive reversibility test might base solely relative ( 12 % ) postbronchodilator response . 8 . All patient neversmokers exsmokers stop smoke least one year prior enrolment . 9 . Patients able use Respimat® inhaler correctly . 10 . Patients must able perform trial related procedure include technically acceptable spirometric manoeuvre , accord American Thoracic Society ( ATS ) standard use electronic diary/peak flow meter . Exclusion criterion : 1 . Patients significant disease asthma . 2 . Patients history congenital acquire heart disease , and/or hospitalise cardiac syncope failure past year . 3 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention ( e. g. pacemaker implantation ) change drug therapy within past year . 4 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . 5 . Patients lung disease asthma , e.g . cystic fibrosis ( CF ) . In case expremature infant , history significant bronchopulmonary dysplasia ( BPD ) regard exclusion criterion 6 . Patients significant alcohol drug abuse within past two year . 7 . Patients know hypersensitivity anticholinergic drug , benzalkonium chloride ( BAC ) , ethylenediaminetetraacetic acid ( EDTA ) component tiotropium inhalation solution . 8 . Pregnant nursing adolescent female patient , include female patient positive Beta HCG ( serum pregnancy ) test screen ( visit 1 ) . 9 . Sexually active female patient childbearing potential use highly effective method birth control . 10 . Patients know narrowangle glaucoma , disease anticholinergic treatment contraindicate . 11 . Patients renal impairment , define creatinine clearance le 50 mL/min/1.73 m2 body surface area ( BSA ) calculate Schwartz Formula .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>